case_images: PMC5488110_01
case_images: Patient flow diagram
case_images: 40487_2017_40_Fig1_HTML.jpg
case_images: PMC5488110_02_40487_2017_40_Fig1_HTML.jpg
case_images: Fig1
case_images: Of the 10 patients who switched from degarelix, three received the leuprorelin acetate implant before radiotherapy as neoadjuvant therapy and the seven men who received it as adjuvant therapy are still receiving the implant (Fig. 1).
case_images: PMC5488110_02
case_images: Patient flow diagram
case_images: 40487_2017_40_Fig1_HTML.jpg
case_images: PMC5488110_02_40487_2017_40_Fig1_HTML.jpg
case_images: Fig1
case_images: Of the 10 patients who switched from degarelix, three received the leuprorelin acetate implant before radiotherapy as neoadjuvant therapy and the seven men who received it as adjuvant therapy are still receiving the implant (Fig. 1).
case_images: PSA levels of 10 patients measured before and after switching from an LHRH antagonist to an LHRH agonist
case_images: 40487_2017_40_Fig2_HTML.jpg
case_images: PMC5488110_02_40487_2017_40_Fig2_HTML.jpg
case_images: Fig2
case_images: PSA measurement, 1-6 months, mean 2.2 +- 1.6 (SD)]. PSA levels were comparable or reduced from those measured prior to switching, showing that efficacy was not compromised (Fig. 2).